pipeline candidates

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.

Vertex Pharmaceuticals needs 26% annual growth to turn $100K into $1M by 2036, but its maturing cystic fibrosis franchise and competitive pressures make this ambitious target unlikely despite solid fundamentals.